|  |  |
|
|
 |
|
How We Build It for quotes call 979 542 0125 or lynco@verizon.net
Erythromycin online review) and for my second opinion on the same topic (which I shared more recently). My third review, published in the December 2010 issue of Journal Infection, is on a drug called cidofovir (ofcovir) which has also been shown as having benefits and risks against meningococcal infection.
Since then I have continued a research project I started in December 2011. am using the same criteria I used when reviewing cidofovir as the drugs I review - efficacy, safety and impact on cancer. As I reviewed cidofovir decided to review another drug with benefits and risks which I had previously written about for my Erythromycin 250mg $51.09 - $0.57 Per pill 2004 review of azithromycin (azithromycin online review). I am using the same criteria I used when reviewing azithromycin.
Reviews in order of date publication.
January 2010
Cidofovir, a new drug for preventing and treating meningococcal disease
March 2010
Cidofovir, a novel antibiotic which has proven efficacy in preventing and treating acute infections from meningococcal disease
April 2010
Cidofovir, a novel antifungal drug which has proven efficacy against a new generation of drug resistant strains MenPap
May 2010
Cidofovir, a new and efficient combination antibiotic for treating patients infected with a group of bacteria known as the "MenPap"-coccidioidomycosis
May 2010
Azithromycin, the first drug to be licensed for cancer patients
June 2010
Cidofovir, a novel compound for treating meningococcal infections
June 2010
Azithromycin, the first drug to be licensed for healthy patients
June 2010
Summary of my MenPap articles
May 2011
Cidofovir and azithromycin are currently the only drugs available in both developed and developing countries for the prevention of and treatment meningococcal disease. Both have the potential to be new therapies for some of the most best drugstore highlighter australia common forms meningibrosis and meningitis in developed countries. On the basis of this review, we judge that either of these agents could be used to treat meningitis and/or meningititis following an initial treatment with azithromycin, whether after the initial infection is already established or on the basis of meningitis that will not be treatable by the traditional antimicrobial therapy alone.
The potential for a combination of cidofovir and azithromycin, in particular against the meningococcal bacterium MenPap (Coccidioidomycosis), should allow for some further improvement in treatment outcomes than might previously have been expected. This was a very important consideration in the development of this review. There were some areas where even this could be seen less likely, because these agents have shown little or no clear benefit against this disease.
In addition, even if cidofovir and azithromycin are relatively safe compared with existing therapies, both agents have significant side effects that require special counselling and patient care. Patients treated with cidofovir tend to show a higher incidence of drug-induced hyperlipidaemia and myopathy, whereas azithromycin may have an increased incidence of hyperglycaemia and gastrointestinal disturbances.
My concern is that, if neither drug may be fully effective against this disease, these two agents could easily be considered "medically useless for people with meningitis or meningitis-free." This.
- Krakow am See
- GroĆ-Umstadt
- Sinzig
- Rennerod
- Werne
Erythromycin 250mg $64.34 - $0.54 Per pill
Erythromycin 500mg $35.11 - $1.17 Per pill
Erythromycin 500mg $56.43 - $0.94 Per pill
Erythromycin 500mg $77.76 - $0.86 Per pill
Erythromycin 500mg $99.08 - $0.83 Per pill
Erythromycin is used for treatin |
|
